新加坡证券交易所 | 火力全开

 
图1:2020年四季度与2020财年与去年同期的业绩对比


 
积极方面

+ 2020年四季度,现金股业务将看到散户投资者的持续参与。据观察所有部门客户的交易活动均有所增加,本季度该部门的交易和清算收入同比增长了48.3%,收入从4440万新元增加至6580万新元。低迷的市况提供了有利的投资机会,因为散户投资者的兴趣呈现持续升温的势头。新交所观察到,今年新增了64,000个零售CDP账户,而去年只有45,000个 (同比增长40%)。
+ 通过收购Scientific Beta,2020年四季度的DCI收益同比增长了39.5%。2020下半年,合并了Scientific Beta的收益,使该部门在2020财年的收入增加了1440万新元。除了有机增长外,来自Scientific Beta的全年收入贡献将为该部门在2021财年的收入增长提供支撑。
+ 由于收益的持续增长,拟议末期股息为每股8.0分 (2020年三季度的每股派息为7.0分)。展望未来,新交所预计每年将派发32分股息,同比增长7%。这符合新交所的政策,即根据公司的长期增长前景,支付可持续和不断增长的股息。
 

消极方面

– 由于市场环境较差,融资活动仍然低迷。2020年四季度,由于新冠疫情爆发,各公司推迟了IPO,致使上市收入和企业活动收入同比分别下降了5.2%和27.5%。尽管如此,随着经济开始复苏,融资活动有望回归。
 

前景

战略性收购为未来的增长奠定了基础。继2020年三季度收购指数公司Scientific Beta后,新交所还在6月底全面收购了外汇交易平台BidFX,将其足迹扩展至外汇OTC市场。这两宗收购都将通过扩大新交所的产品系列,对公司当前的业务构成补充,并为公司提供了交叉销售机会。

Scientific Beta在2020财年,为新交所的DCI业务的半年收入(1440万新元)提供了有意义的贡献。它将赋予新交所推出新产品的能力,从smart beta投资到ESG投资,以迎合市场参与者的需求。

BidFX为新交所提供了进入外汇OTC市场的渠道,这将补充其现有的外汇期货产品。截至2020年6月,在6.6万亿美元的行业规模中,BidFX录得的日均交易量(ADV)为310亿美元,自2017年以来,该公司已实现的CAGR(复合年增长率)为57%。该平台为包括银行,对冲基金和资产管理公司在内的,全球100多家机构客户,提供了充足的有机增长空间。

对成套产品的积极管理,保证了业务长存。随着5月宣布于2021年2月终止非新加坡MSCI指数期货产品,新交所已与FTSE合作推出FTSE台湾指数期货,以取代即将到期的最大合约(即MSCI台湾指数期货)。该新产品还获得了美国商品期货交易委员会的批准,可以在美国市场销售和分销,而此前新交所的MSCI产品却无法获得这一批准。已与FTSE制定了计划,在MSCI于2021年2月到期之前,将推出一系列扩展产品。

 
 
投资行动

在2020年四季度的持续盈利下,我们升级至买入建议,并上调目标价至9.45新元 (先前目标价为9.28新元)。我们的目标价与21.4倍的市盈率挂钩,比新交所的5年平均值低1 SD(标准差)。当前的交易价格估值颇具吸引力(18.5倍市盈率),并将季度股息上调至每股8.0分,提供了3.9%的适度收益率。
 

图2:将我们的估值与新交所5年市盈率的-1SD作为基准

 

如果有想了解更多全球股市资讯,请关注微信公众号 “辉立资本新加坡” (SGPSPL)。同时提供在线免费开设股票账户,一个账户轻松交易全球股票和ETF

美股,港股,新加坡股,中国A股,越南股票,韩国股票,德国股票,马来西亚股票,泰国股票,印尼股票,菲律宾股票,日本股票,澳大利亚股票,台湾股票,加拿大股票,英国股票,法国股票,荷兰股票,葡萄牙股票,比利时股票,土耳其股票

如果本文是英文翻译版本,一切请以英文为准

联系我们开设账户

需要帮助吗?请分享您的详细资料,我们会给您答复。

IMPORTANT INFORMATION

This material is provided by Phillip Capital Management (S) Ltd (“PCM”) for general information only and does not constitute a recommendation, an offer to sell, or a solicitation of any offer to invest in any of the exchange-traded fund (“ETF”) or the unit trust (“Products”) mentioned herein. It does not have any regard to your specific investment objectives, financial situation and any of your particular needs. You should read the Prospectus and the accompanying Product Highlights Sheet (“PHS”) for key features, key risks and other important information of the Products and obtain advice from a financial adviser (“FA“) pursuant to a separate engagement before making a commitment to invest in the Products. In the event that you choose not to obtain advice from a FA, you should assess whether the Products are suitable for you before proceeding to invest. A copy of the Prospectus and PHS are available from PCM, any of its Participating Dealers (“PDs“) for the ETF, or any of its authorised distributors for the unit trust managed by PCM.  

An ETF is not like a typical unit trust as the units of the ETF (the “Units“) are to be listed and traded like any share on the Singapore Exchange Securities Trading Limited (“SGX-ST”). Listing on the SGX-ST does not guarantee a liquid market for the Units which may be traded at prices above or below its NAV or may be suspended or delisted. Investors may buy or sell the Units on SGX-ST when it is listed. Investors cannot create or redeem Units directly with PCM and have no rights to request PCM to redeem or purchase their Units. Creation and redemption of Units are through PDs if investors are clients of the PDs, who have no obligation to agree to create or redeem Units on behalf of any investor and may impose terms and conditions in connection with such creation or redemption orders. Please refer to the Prospectus of the ETF for more details.  

Investments are subject to investment risks including the possible loss of the principal amount invested. The purchase of a unit in a fund is not the same as placing your money on deposit with a bank or deposit-taking company. There is no guarantee as to the amount of capital invested or return received. The value of the units and the income accruing to the units may fall or rise. Past performance is not necessarily indicative of the future or likely performance of the Products. There can be no assurance that investment objectives will be achieved.  

Where applicable, fund(s) may invest in financial derivatives and/or participate in securities lending and repurchase transactions for the purpose of hedging and/or efficient portfolio management, subject to the relevant regulatory requirements. PCM reserves the discretion to determine if currency exposure should be hedged actively, passively or not at all, in the best interest of the Products.  

The regular dividend distributions, out of either income and/or capital, are not guaranteed and subject to PCM’s discretion. Past payout yields and payments do not represent future payout yields and payments. Such dividend distributions will reduce the available capital for reinvestment and may result in an immediate decrease in the net asset value (“NAV”) of the Products. Please refer to <www.phillipfunds.com> for more information in relation to the dividend distributions.  

The information provided herein may be obtained or compiled from public and/or third party sources that PCM has no reason to believe are unreliable. Any opinion or view herein is an expression of belief of the individual author or the indicated source (as applicable) only. PCM makes no representation or warranty that such information is accurate, complete, verified or should be relied upon as such. The information does not constitute, and should not be used as a substitute for tax, legal or investment advice.  

The information herein are not for any person in any jurisdiction or country where such distribution or availability for use would contravene any applicable law or regulation or would subject PCM to any registration or licensing requirement in such jurisdiction or country. The Products is not offered to U.S. Persons. PhillipCapital Group of Companies, including PCM, their affiliates and/or their officers, directors and/or employees may own or have positions in the Products. Any member of the PhillipCapital Group of Companies may have acted upon or used the information, analyses and opinions herein before they have been published. 

This advertisement has not been reviewed by the Monetary Authority of Singapore.  

 

Phillip Capital Management (S) Ltd (Co. Reg. No. 199905233W)  
250 North Bridge Road #06-00, Raffles City Tower ,Singapore 179101 
Tel: (65) 6230 8133 Fax: (65) 65383066 www.phillipfunds.com